135 related articles for article (PubMed ID: 37698272)
1. SARS-CoV-2 inactivation in laboratory animal tissues with 4% formaldehyde or 5% glutaraldehyde for transfer to biosafety level 1 laboratories.
Pilchová V; Elmontaser Mergani A; Clever S; Ciurkiewicz M; Becker K; Gerhauser I; Baumgärtner W; Volz A; von Köckritz-Blickwede M; Schulz C
Vet Pathol; 2024 Mar; 61(2):201-206. PubMed ID: 37698272
[TBL] [Abstract][Full Text] [Related]
2. Assessment of inactivation procedures for SARS-CoV-2.
Auerswald H; Yann S; Dul S; In S; Dussart P; Martin NJ; Karlsson EA; Garcia-Rivera JA
J Gen Virol; 2021 Mar; 102(3):. PubMed ID: 33416462
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of stability and inactivation methods of SARS-CoV-2 in context of laboratory settings.
Widera M; Westhaus S; Rabenau HF; Hoehl S; Bojkova D; Cinatl J; Ciesek S
Med Microbiol Immunol; 2021 Aug; 210(4):235-244. PubMed ID: 34196781
[TBL] [Abstract][Full Text] [Related]
4. β-Propiolactone (BPL)-inactivation of SARS-Co-V-2: In vitro validation with focus on saliva from COVID-19 patients for scent dog training.
Pilchová V; Prajeeth CK; Jendrny P; Twele F; Meller S; Pink I; Fathi A; Addo MM; Volk HA; Osterhaus A; von Köckritz-Blickwede M; Schulz C
J Virol Methods; 2023 Jul; 317():114733. PubMed ID: 37068591
[TBL] [Abstract][Full Text] [Related]
5. Efficient inactivation of Burkholderia pseudomallei or Francisella tularensis in infected cells for safe removal from biosafety level 3 containment laboratories.
Emery FD; Stabenow JM; Miller MA
Pathog Dis; 2014 Jul; 71(2):276-81. PubMed ID: 24449562
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV.
Darnell ME; Subbarao K; Feinstone SM; Taylor DR
J Virol Methods; 2004 Oct; 121(1):85-91. PubMed ID: 15350737
[TBL] [Abstract][Full Text] [Related]
7. Methods of Inactivation of SARS-CoV-2 for Downstream Biological Assays.
Patterson EI; Prince T; Anderson ER; Casas-Sanchez A; Smith SL; Cansado-Utrilla C; Solomon T; Griffiths MJ; Acosta-Serrano Á; Turtle L; Hughes GL
J Infect Dis; 2020 Oct; 222(9):1462-1467. PubMed ID: 32798217
[TBL] [Abstract][Full Text] [Related]
8. Heat Inactivation of Different Types of SARS-CoV-2 Samples: What Protocols for Biosafety, Molecular Detection and Serological Diagnostics?
Pastorino B; Touret F; Gilles M; de Lamballerie X; Charrel RN
Viruses; 2020 Jul; 12(7):. PubMed ID: 32646015
[TBL] [Abstract][Full Text] [Related]
9. Virus Inactivation by Formaldehyde and Common Lysis Buffers.
Seeburg U; Urda L; Otte F; Lett MJ; Caimi S; Mittelholzer C; Klimkait T
Viruses; 2023 Aug; 15(8):. PubMed ID: 37632035
[TBL] [Abstract][Full Text] [Related]
10. Selection and application of biological safety cabinets in diagnostic and research laboratories with special emphasis on COVID-19.
Pawar SD; Khare AB; Keng SS; Kode SS; Tare DS; Singh DK; More RL; Mullick J
Rev Sci Instrum; 2021 Aug; 92(8):081401. PubMed ID: 34470433
[TBL] [Abstract][Full Text] [Related]
11. Viral Inactivation with Emphasis on SARS-CoV-2 Using Physical and Chemical Disinfectants.
Fadaei A
ScientificWorldJournal; 2021; 2021():9342748. PubMed ID: 34712107
[TBL] [Abstract][Full Text] [Related]
12. Laboratory biosafety measures involving SARS-CoV-2 and the classification as a Risk Group 3 biological agent.
Kaufer AM; Theis T; Lau KA; Gray JL; Rawlinson WD
Pathology; 2020 Dec; 52(7):790-795. PubMed ID: 33070960
[TBL] [Abstract][Full Text] [Related]
13. Biorisk Management for SARS-CoV-2 Research in a Biosafety Level-3 Core Facility.
Joseph T; Phyu S; Se-Thoe SY; Chu JJH
Methods Mol Biol; 2022; 2452():441-464. PubMed ID: 35554920
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of SARS-CoV-2 and COVID-19 Patient Samples for Contemporary Immunology and Metabolomics Studies.
Eddins DJ; Bassit LC; Chandler JD; Haddad NS; Musall KL; Yang J; Kosters A; Dobosh BS; Hernández MR; Ramonell RP; Tirouvanziam RM; Lee FE; Zandi K; Schinazi RF; Ghosn EEB
Immunohorizons; 2022 Feb; 6(2):144-155. PubMed ID: 35173021
[TBL] [Abstract][Full Text] [Related]
15. Validating the inactivation of viral pathogens with a focus on SARS-CoV-2 to safely transfer samples from high-containment laboratories.
Chaki SP; Kahl-McDonagh MM; Neuman BW; Zuelke KA
Front Cell Infect Microbiol; 2024; 14():1292467. PubMed ID: 38510962
[TBL] [Abstract][Full Text] [Related]
16. Preparation of noninfectious scRNAseq samples from SARS-CoV-2-infected epithelial cells.
Osborn RM; Leach J; Zanche M; Ashton JM; Chu C; Thakar J; Dewhurst S; Rosenberger S; Pavelka M; Pryhuber GS; Mariani TJ; Anderson CS
PLoS One; 2023; 18(2):e0281898. PubMed ID: 36827401
[TBL] [Abstract][Full Text] [Related]
17. Extracellular Vesicles Analysis in the COVID-19 Era: Insights on Serum Inactivation Protocols towards Downstream Isolation and Analysis.
Frigerio R; Musicò A; Brucale M; Ridolfi A; Galbiati S; Vago R; Bergamaschi G; Ferretti AM; Chiari M; Valle F; Gori A; Cretich M
Cells; 2021 Mar; 10(3):. PubMed ID: 33806297
[TBL] [Abstract][Full Text] [Related]
18. UV Inactivation of SARS-CoV-2 across the UVC Spectrum: KrCl* Excimer, Mercury-Vapor, and Light-Emitting-Diode (LED) Sources.
Ma B; Gundy PM; Gerba CP; Sobsey MD; Linden KG
Appl Environ Microbiol; 2021 Oct; 87(22):e0153221. PubMed ID: 34495736
[TBL] [Abstract][Full Text] [Related]
19. In Vitro Inactivation of SARS-CoV-2 Using Gamma Radiation.
Leung A; Tran K; Audet J; Lavineway S; Bastien N; Krishnan J
Appl Biosaf; 2020 Sep; 25(3):157-160. PubMed ID: 36035758
[TBL] [Abstract][Full Text] [Related]
20. Heat inactivation of clinical COVID-19 samples on an industrial scale for low risk and efficient high-throughput qRT-PCR diagnostic testing.
Delpuech O; Douthwaite JA; Hill T; Niranjan D; Malintan NT; Duvoisin H; Elliott J; Goodfellow I; Hosmillo M; Orton AL; Taylor MA; Brankin C; Pitt H; Ross-Thriepland D; Siek M; Cuthbert A; Richards I; Ferdinand JR; Barker C; Shaw R; Ariani C; Waddell I; Rees S; Green C; Clark R; Upadhyay A; Howes R
Sci Rep; 2022 Feb; 12(1):2883. PubMed ID: 35190592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
